* If the product has intellectual property rights, a license granted is must or contact us.
Cancer-Targeting Compound 1
Introduction of 1007581-62-5 :
Cancer-Targeting Compound 1 is used in the research of hormone-related cancer, extracted from patent WO 2008021331 A2. In Vitro: Cancer-Targeting Compound 1 is useful for the research of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.